lapatinib has been researched along with Sensitivity and Specificity in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, MQ; Kocan, GP; Li, F; Pai, S | 1 |
| Hay, JW; Le, QA | 1 |
| Clynes, M; McMahon, G; O'Connor, R; Roche, S | 1 |
| Cheon, S; Cho, H; Espina, V; Havaleshko, DM; Lee, JK; Liotta, LA; Owens, CR; Petricoin, EF; Smith, SC; Theodorescu, D; Wulfkuhle, JD | 1 |
| Griffiths, TR; Kriajevska, M; McHugh, LA; Mellon, JK | 1 |
| Ben Ahmed, S; Blackwell, K; Boussen, H; Citrin, DL; DeSilvio, ML; Harris, J; Johnston, S; Kaufman, B; Lombardi, DP; LoRusso, P; Salazar, V; Spector, NL; Trudeau, M; Westlund, RE; Zaks, TZ | 1 |
1 trial(s) available for lapatinib and Sensitivity and Specificity
| Article | Year |
|---|---|
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Female; Humans; Immunoenzyme Techniques; Inflammation; Lapatinib; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Sensitivity and Specificity; Skin Neoplasms | 2008 |
5 other study(ies) available for lapatinib and Sensitivity and Specificity
| Article | Year |
|---|---|
A sensitive LC-MS-MS assay for the determination of lapatinib in human plasma in subjects with end-stage renal disease receiving hemodialysis.
Topics: Chromatography, Liquid; Drug Stability; Humans; Kidney Failure, Chronic; Lapatinib; Linear Models; Neoplasms; Quinazolines; Renal Dialysis; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quality of Life; Quinazolines; Sensitivity and Specificity | 2009 |
Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dasatinib; Humans; Lapatinib; Limit of Detection; Mass Spectrometry; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Sensitivity and Specificity; Thiazoles | 2009 |
Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression; Gene Expression Profiling; Humans; Lapatinib; Models, Molecular; Oligonucleotide Array Sequence Analysis; Quinazolines; Sensitivity and Specificity; Signal Transduction; Urinary Bladder Neoplasms | 2009 |
Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Sensitivity and Specificity; Urinary Bladder Neoplasms | 2007 |